A potent EGFR tyrosine kinase inhibitor
Tarceva is different from conventional chemotherapies and has been shown to potently inhibit tyrosine kinase phosphorylation of EGFR. Learn more about cancer cell proliferation, EGFR, dysregulation of EGFR and Tarceva’s mechanism of inhibition.
Approval and labeling information
Tarceva is approved in most European countries. Download the labeling information in your own language to print or save to your computer.
Tarceva.com
This site is only intended for use by healthcare professionals outside of the US. If you are a US resident, please visit www.tarceva.com.
ECCO 15 ESMO 34, Berlin, 2009
Watch Dr Schumann speaking about results from a study of erlotinib in advanced non-small-cell lung cancer (NSCLC), ECCO 15 ESMO 34, Berlin, 2009
- Disclaimer: Tarceva.net is a compreshesive resource for healthcare professionals outside the US. If you are a US resident please visit www.Tarceva.com. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
- © 2010 F. Hoffmann-La Roche Ltd.